Advancing Theranostic Prostate Cancer Trial

Clarity Pharmaceuticals (ASX: CU6) progresses to the multi-dose phase in their SECuRE trial targeting mCRPC using 64Cu/67Cu-SAR-bisPSMA. Cohort 3, comprising 6 participants, completed therapy with 67Cu-SAR-bisPSMA at a 12GBq dose level without reported dose-limiting toxicities. Overall, the trial demonstrated a favorable safety profile across cohorts 1 to 3.

With encouraging reductions in PSA levels, particularly notable in cohorts 2 and 3, the trial moves forward to cohort 4 for multi-dose evaluation. Notably, participants in cohort 3 had extensive prior treatments, indicating the trial's relevance for refractory cases. Recruitment for cohort 4 has commenced in the US, targeting participants for multiple treatment cycles at the 12GBq dose level. This progression marks a significant step in enhancing treatment outcomes for metastatic castrate-resistant prostate cancer.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com